Unicycive Therapeutics, Inc.
UNCY
$5.09
$0.061.19%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 41.03% | 17.39% | 25.20% | 36.56% | 105.80% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 45.63% | 5.61% | -22.00% | 17.45% | -5.92% |
| Operating Income | -45.63% | -5.61% | 22.00% | -17.45% | 5.92% |
| Income Before Tax | 73.29% | -2,349.65% | 31.86% | -46.75% | -165.42% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 73.29% | -2,349.65% | 31.86% | -46.75% | -165.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 73.29% | -2,349.65% | 31.86% | -46.75% | -165.42% |
| EBIT | -45.63% | -5.61% | 22.00% | -17.45% | 5.92% |
| EBITDA | -45.67% | -5.61% | 22.04% | -17.41% | 6.00% |
| EPS Basic | 87.79% | -1,327.23% | 66.39% | 27.75% | -113.34% |
| Normalized Basic EPS | 87.79% | -1,199.02% | 66.38% | 27.73% | -120.16% |
| EPS Diluted | 87.79% | -7.61% | 66.39% | 27.75% | 64.20% |
| Normalized Diluted EPS | 87.79% | -1,263.89% | 66.38% | 27.73% | -150.01% |
| Average Basic Shares Outstanding | 118.80% | 104.66% | 102.72% | 103.11% | 224.47% |
| Average Diluted Shares Outstanding | 118.80% | 93.06% | 102.72% | 103.11% | 30.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |